Anne Wojcicki, co-founder and former CEO of 23andMe, secured purchase of the company’s assets for $305 million through her nonprofit, TTAM Research Institute, winning a last-minute auction over Regeneron. The deal includes 23andMe's Personal Genome Service and other services, with commitments to uphold privacy, consumer protections, and research opt-outs. A consumer privacy advisory board is planned post-sale. The bankruptcy court will hold a hearing June 17. Wojcicki’s acquisition aims to preserve 23andMe’s founding mission and ensure enhanced data protections for consumers.